A Phase 1, Open-label Study to Compare the Pharmacokinetics and Pharmacodynamics of Warfarin and Esmolol in the Absence and Presence of MEDI0382 in Healthy Subjects
Phase of Trial: Phase I
Latest Information Update: 22 Dec 2017
At a glance
- Drugs MEDI 0382 (Primary) ; Esmolol; Warfarin
- Indications Obesity; Type 2 diabetes mellitus
- Focus Therapeutic Use
- Sponsors MedImmune
- 15 Dec 2017 Planned End Date changed from 7 Mar 2018 to 9 Mar 2018.
- 15 Dec 2017 Planned primary completion date changed from 7 Mar 2018 to 9 Mar 2018.
- 15 Dec 2017 Status changed from not yet recruiting to recruiting.